SELECTBIO - Trends in Cancer Models 2021 Keynote Speakers

Home

Agenda

Keynote Speakers

Registration

Venue

James Clinton

Senior Scientist, American Type Culture Collection (ATCC)

James Clinton is a Senior Scientist and group leader in Research & Development at ATCC. His team is working on the development and commercialization of advanced, physiologically relevant in vitro models utilizing primary and induced pluripotent stem cells, as well as exploring recently emerging culture techniques such as 3D organoids and co-culture approaches.

Mindy Goldsborough

Chief Scientific Officer, ATCC

As the Chief Science and Technology Officer for ATCC, Mindy works across ATCC’s business units and functions to develop and implement the scientific and technology strategy in support of organizational goals. Additionally, she oversees the ATCC Cell Systems (ACS) business unit located within Maryland’s High Technology Corridor in Gaithersburg, MD. ACS is the innovative cell biology product and technology development arm of ATCC. Its current focus is in areas of functional cell biology supporting basic and translational research.

Prior to ATCC, Mindy was Director of R&D for BD Biosciences’ Advanced Bioprocessing group. Her previous work includes senior R&D roles at BD Biosciences’ Bioimaging business (formerly Atto Biosciences) and Life Technologies, where she led R&D efforts in DNA-based diagnostics, stem cell biology, forensics, and nucleic acid purification. Mindy has more than 25 years of product and technology development expertise in cell and molecular biology. Several products that she helped develop during her career are still market standards today.

Mindy earned her Ph.D. in Genetics from The George Washington University, and completed her dissertation research and post-doctoral work at The National Institutes of Health, National Cancer Institute.

M. Laura Martin

Director of ex vivo Models, Englander Institute for Precision Medicine, Weill Cornell Medicine

M. Laura Martin, Ph.D., is leading the Organoid Platform at Englander Institute for Precision Medicine. The Organoid Platform focus in the utilization of patient-derived models of cancer, studying the functional impact of genetic and epigenetic alterations in preclinical models, and investigating the potential to translate these findings to clinical relevance. She is also focusing in the expansion of the ex-vivo model program, improve the rate of successful model development, and increased applications for which ex-vivo models are used for research across campuses.